Peptide synthesis companies Activotec (UK) and Creosalus (USA) has announced a distribution agreement to boost worldwide sales and support for their products. Activotec will exclusively sell in Europe the Creosalus multiple peptide synthesizer, the Tetras, and the chemical product range. Creosalus will exclusively sell in the USA and Canada the Activotec synthesizer range including the Activo-P11 and P14 Peptide Synthesizers and the Activo-S44 oligosaccharide synthesizer.

Both Companies are specialized in peptide and organic synthesis and have decades of experience developing, selling and supporting synthesizers. This agreement brings together expertise that is second to none in this field.

Activotec is based in Cambridge, UK and has an extremely knowledgeable team of support people including chemists and engineers in Europe. With a very well established customer base for its synthesizers, Activotec is ideally placed to add the Creosalus products to its portfolio and provide service and application support throughout all of Europe.

Chris Littlewood, Chief Executive of Activotec, commented “this is a very exciting collaboration between the two Companies, it provides the necessary sales and technical support to enable Activotec to launch its products into the US & Canada. We have seen in Europe the need for a new multiple peptide synthesizer with the proper level of technical support; the Tetras from Creosalus supported by us will fulfil that need and add very nicely to our synthesizer range.